WO2004080487A1 - 歯ぎしりの予防剤または治療剤 - Google Patents
歯ぎしりの予防剤または治療剤 Download PDFInfo
- Publication number
- WO2004080487A1 WO2004080487A1 PCT/JP2004/000939 JP2004000939W WO2004080487A1 WO 2004080487 A1 WO2004080487 A1 WO 2004080487A1 JP 2004000939 W JP2004000939 W JP 2004000939W WO 2004080487 A1 WO2004080487 A1 WO 2004080487A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bruxism
- therapeutic agent
- proton pump
- prophylactic
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an agent for preventing or treating bruxism, and more particularly, an agent for preventing or treating bruxism and diseases related to bruxism, comprising as an active ingredient a drug having an effect of suppressing gastric acid reflux in the esophagus.
- Bruxism is considered to be abnormal functional movements during sleep, oral habits or parasomnia, causing tooth abrasion ⁇ fracture, masticatory muscle discomfort ⁇ pain, temporomandibular disorders, etc. It is known to have a major adverse effect.
- Non-Patent Document 1 Regarding the appearance of bruxism, it was previously thought that occlusion was involved, but in recent years it has become known that occlusion hardly contributes to the appearance of bruxism (for example, see Non-Patent Document 1).
- An object of the present invention is to provide an effective and fundamental preventive or therapeutic agent for bruxism and bruxism-related diseases.
- the present inventors have focused on the fact that gastric acid reflux in the esophagus during sleep causes bruxism, and inferred that prevention or treatment of bruxism would be possible if gastric acid reflux in the esophagus could be prevented.
- the present inventors have conducted intensive studies on the prevention or treatment of bruxism, and as a result, a gastric acid secretion inhibitor represented by a proton pump inhibitor has been shown to be effective in preventing bruxism and diseases associated with bruxism. It was found for the first time that it was useful in prevention or treatment, and the present invention was completed.
- ⁇ 2> proton pump inhibitors, histamine H 2 receptor antagonist or Ashiddopon preventive agent for teeth grinding comprising as an active ingredient at least one selected from the flop antagonist or a therapeutic agent:
- Prophylactic or therapeutic agent for bruxism containing a proton pump inhibitor as an active ingredient ⁇ 5> If the proton pump inhibitor is rabebrazole, omebrazole, esomeprazole, lansoprazole, pantoprazole or tenatoprazole, or a salt thereof, the hydrate is a hydrate thereof.
- ⁇ 7> The prophylactic or therapeutic agent according to any one of ⁇ 2> to ⁇ 4>, wherein the proton pump inhibitor is sodium salt of rabebrazole.
- ⁇ 7-1> The prophylactic or therapeutic agent according to any one of ⁇ 1> to ⁇ 4>, wherein the proton pump inhibitor is omebrazole or a salt thereof.
- ⁇ 7-2> The prophylactic or therapeutic agent according to any one of ⁇ 1> to ⁇ 4>, wherein the proton pump inhibitor is esomeprazole or a salt thereof.
- ⁇ 7> 4> The prophylactic or therapeutic agent according to any one of ⁇ 1> to ⁇ 4>, wherein the proton pump inhibitor is pantoprazole or a salt thereof.
- histamine H 2 receptor antagonist is cimetidine, ranitidine, famotidine, mouth Kisachijin, nizatidine or lafutidine or foil 2> or walk in their salt 3>, wherein the prophylactic or therapeutic agents:
- Prophylactic or therapeutic agent for bruxism-related diseases containing a gastric acid secretion inhibitor as an active ingredient:
- a prophylactic or therapeutic agent for a bruxism-related disease comprising as an active ingredient at least one selected from a proton pump inhibitor, a histamine H 2 receptor antagonist and an acid pump antagonist:
- the proton pump inhibitor is rabebrazole, omebrazole, esomeprazole, lansoprazole, pantoprazole or tenatoprazole, or a salt or hydrate thereof, or the prophylaxis according to any one of ⁇ 10> to ⁇ 12>.
- Agent or therapeutic agent :
- ⁇ 14> The prophylactic or therapeutic agent according to any one of ⁇ 10> to ⁇ 12>, wherein the proton pump inhibitor is rabeprazole or a salt thereof:
- the prophylactic or therapeutic agent according to any one of 1 to 5> the proton pump inhibitor is sodium salt of rabebrazole.
- ⁇ 15> The prophylactic or therapeutic agent according to any one of ⁇ 1> to ⁇ 15>, wherein the proton pump inhibitor is omebrazole or a salt thereof.
- ⁇ 15_2> The prophylactic or therapeutic agent according to any one of ⁇ 1> to ⁇ 12>, wherein the proton pump inhibitor is esomeprazole or a salt thereof.
- ⁇ 15-5> The prophylactic or therapeutic agent according to any one of ⁇ 1> to ⁇ 12>, wherein the proton pump inhibitor is pantoprazole or a salt thereof.
- histamine H 2 receptor antagonist is cimetidine, ranitidine, famotidine, mouth Kisachijin, 1 0 walk in nizatidine or lafutidine, or a salt thereof> or ⁇ 1 1> claimed in any one of the prophylactic or therapeutic agents:
- the diseases related to bruxism are temporomandibular disorders, tooth hypersensitivity, occlusal trauma, tooth abrasion, tooth wedge loss, gingival regression, tooth fracture, tooth sway, root resorption, Alveolar bone absorption, masseter hypertrophy, masticatory muscle pain, fracture of crown restoration, omission of crown restoration or headache 9> to ⁇ 16> Hey
- the disease related to bruxism is temporomandibular disorder ⁇ 9> to ⁇ 16> Any Or the prophylactic or therapeutic agent according to 1 above.
- ⁇ 20> A method for preventing or treating bruxism-related diseases by administering an effective amount of a gastric acid secretion inhibitor:
- FIG. 1 shows (A) changes in esophageal pH and (B) temporal muscle activity during sleep (40 minutes) in bruxism patients.
- Figure 2 shows temporal muscle activity during sleep (4 hours) in patients with bruxism after (left) placebo administration and (right) proton pump inhibitor administration, respectively.
- prophylactic or therapeutic agent refers to an agent containing a single agent or an agent containing multiple agents.
- An agent containing multiple drugs refers to an agent obtained by simultaneously formulating a single drug, or multiple drugs obtained by separately formulating a single drug, simultaneously or for a certain period of time effective for prevention or treatment.
- gastric acid secretion inhibitor refers to a drug that suppresses gastric acid secretion.
- gastric acid secretion inhibitor examples include Chinese herbs or herbal extracts such as antagonists, antacids, and funnel extracts.
- proton pump inhibitor refers to a drug that modifies the SH group of a proton pump (H +, K + —ATPase) to inhibit enzyme activity and suppress acid secretion.
- the proton pump inhibitor usually refers to a compound having a benzimidazole skeleton or an imidazopyridine skeleton.
- Specific examples of the proton pump inhibitor include, but are not limited to, rabeprazole (1), omebrazole (11), esomeprazolone (II 1), Lansobrazole (IV), pantoprazole (V) or tenatoprazole (V I) or their salts or their hydrates.
- preferred proton pump inhibitors include rabebrazole (I) or its sodium salt, omebrazole (II) or its sodium salt, emesoprazole (III) or its magnesium salt, lansoprazole (Iv), pantoprazole (V ) Or its sodium salt, and more preferably sodium salt of rabebrazole (I).
- rabebrazole is described in the method described in U.S. Pat.No. 5,045,552
- omebrazole is described in U.S. Pat.No. 4,255,5431
- esomeprazole is described in U.S. Pat.
- Lansoprazole was used in the method described in U.S. Pat.No. 4,628,998, and pantobrazole was used in the method described in U.S. Pat. the method, tenatoprazole the method described in U.S. Patent No. 48 0 8 5 9 6 No.
- the "histamine H 2 receptor antagonist" as used herein can be prepared according respectively, stomach histamine H 2 receptor mucosal KabeHoso cells by blocking selectively refers to agents which inhibit gastric acid secretion.
- histamine H 2 receptor antagonists are not limited to the following There are no cimetidines, but cimetidine, ranitidine, famotidine, oral xathidine, nizatidine or laftidine or salts thereof.
- ranitidine is used as ranitidine hydrochloride
- oral xatidine is used as oral xatidine acetate hydrochloride.
- the term “acid pump antagonist” refers to a drug that represses a proton pump to thereby suppress acid secretion.
- Specific examples of the acid pump antagonist include, but are not limited to, the compounds described in US Pat. No. 6,063,782.
- salts for example, a salt with an inorganic acid, a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, a salt with an acidic or basic amino acid and the like are exemplified. Among them, pharmacologically acceptable salts are preferred.
- Preferred examples of salts with inorganic acids include, for example, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Preferred examples of salts with organic acids include, for example, acetic acid, succinic acid And salts with fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and the like.
- Preferred examples of the salt with an inorganic base include an alkali metal salt such as a sodium salt and a potassium salt, an alkaline earth metal salt such as a calcium salt and a magnesium salt, an aluminum salt and an ammonium salt.
- Preferred examples of the salt with an organic base include salts with getylamine, diethanolamine, medalmine, ⁇ , ⁇ ′-dibenzylethylenediamine and the like.
- bruxism refers to a disease caused by bruxism.
- bruxism-related diseases include, but are not limited to, temporomandibular disorders, hypersensitivity of teeth, occlusal trauma, tooth attrition, wedge loss of teeth, gingival regression, Examples include broken teeth, tooth movement, root resorption, alveolar bone resorption, masseter hypertrophy, masticatory muscle pain, broken crown restorations, dropped crown restorations, and headaches.
- preferred diseases include temporomandibular disorders.
- mandibular arthrosis refers to a group of chronic diseases whose main symptoms are pain of the temporomandibular joints and masticatory muscles, joint noise, trismus, or abnormal jaw movements. Disorders, joint capsule and ligament disorders, joint disc disorders, osteoarthritis, etc.
- the administration route and dosage depend on the patient's symptoms, type of ulcer gastritis, degree, age, heart It depends on the liver and kidney function and is not limited.
- a proton pump inhibitor is orally administered to an adult at 0.01 to 100 mg per day.
- the daily adult dose of rabebrazole is preferably between 0.1 and 10 mg as the sodium salt of rabebrazole.
- the daily adult dose of omebrazole is preferably 0 ::! ⁇ 20 mg.
- the daily adult dose of esomeprazole is preferably from 0.1 to 20 mg as the magnesium salt of esomeprazole.
- the daily adult dose of lansoprazole is preferably between 0.1 and 30 mg .
- the daily adult dose of pantoprazole is preferably from 0.1 to 40 mg as the sodium salt of pantoprazole.
- Histamine H 2 receptor antagonist the route of administration when administered to a patient as pre Bozai or therapeutic agents for diseases associated with bruxism Contact Yopi bruxism, dose, administration frequency, patients symptoms, ulcers and gastritis Type, degree, age, heart, liver, kidney function, etc., and are not limited.
- histamine H 2 receptor antagonist a l ⁇ 800mg per day for orally administered to an adult.
- the adult daily dose of cimetidine is preferably l-800 mg, more preferably 50-400 mg.
- the daily adult dose of ranitidine is preferably 5-300 mg, more preferably 30-150 mg, as ranitidine hydrochloride.
- the daily adult dose of famotidine is preferably l-40 mg, more preferably 5-20 mg.
- the daily adult dose of oral xatidine is preferably 5 to: 150 mg as oral xatidine acetate hydrochloride. More preferably, it is 25 to 75 mg.
- the adult daily dose of nizatidine is preferably 30-300 mg, more preferably 50-150 mg.
- the daily daily daily dose of laftidine is preferably 0.5 to 20 mg, more preferably 2.5 to 10 mg.
- Dosage forms include, for example, powders, fine granules, granules, tablets, capsules and the like. At the time of formulation, it can be manufactured by a usual method using a usual formulation carrier. However, since proton pump inhibitors are particularly poor in stability, Japanese Patent Application Laid-Open Nos. (4) A stable preparation can be obtained by the method described in Japanese Patent Application Laid-Open No. 2-222525.
- excipients are added to the active ingredient and, if necessary, a binder, disintegrant, lubricant, coloring agent, etc. Preparations, granules, tablets, capsules, etc.
- Excipients include, for example, lactose, corn starch, sucrose, glucose, mannitol, sorbitol, crystalline cellulose, silicon dioxide, and the like.
- Binders include, for example, polyvinylinole alcohol, polyvinylinoleateol, ethinole cellulose, and the like.
- disintegrants include starch, crystalline cellulose, calcium carbonate, and sodium hydrogen carbonate.
- a proton pump inhibitor and a histami 2 receptor antagonist may be administered to a patient in combination.
- the administration form of is not particularly limited, and it suffices that a proton pump inhibitor and a histamine- 2 receptor antagonist are combined at the time of administration.
- Such dosage forms for example, 1) Pro Tonponpu inhibitor and administration of a formulation obtained by manufacturing Zaika and histamine Eta 2 receptor antagonists at the same time, 2) a proton pump inhibitor and a histamine Eta 2 receptor antagonist simultaneous administration of two kinds of preparations of the agents which have been separately produced, 3) Pro Tonpo pump inhibitor and two kinds of preparations of the histamine 11 2 receptor antagonists have been separately produced, bruxism and Administration at regular intervals effective to prevent or treat bruxism-related diseases (e.g., administration of a proton pump inhibitor, histamine- 2 receptor antagonist, or vice versa) ) And the like.
- bruxism-related diseases e.g., administration of a proton pump inhibitor, histamine- 2 receptor antagonist, or vice versa
- Dose ratio of each agent when combined with a proton pump inhibitor and a histamine Eta 2 receptor antagonist depending on the age, weight, sex, extent of symptoms, dosage form, the specific type of illness Can be selected appropriately.
- the dose ratio of the proton pump inhibitor to the histamine ⁇ 2 receptor antagonist is usually in the range of 10: 1 to 1: 400, preferably 2: 1 to 1: 200 by weight. Should be fine.
- Subjects were administered a placebo and a proton pump inhibitor (rabebrazole 'sodium salt (10 mg; trade name: Pariet (registered trademark): Eisai Co., Ltd.) by a double-blind method, and the method of Test Example 1 was used. According to, the muscle activity of one anterior temporal muscle during sleep was recorded for 4 hours from the first hour to the fifth hour after going to bed.At the same time, video images and audio were recorded, and it was confirmed that bruxism occurred during sleep. Figure 2 shows the results.
- a proton pump inhibitor rabebrazole 'sodium salt (10 mg; trade name: Pariet (registered trademark): Eisai Co., Ltd.
- Fig. 2 (A) show that taking a proton pump inhibitor significantly reduces the frequency of jaw movements (bruxism episodes) with rhythmic temporal muscle activity compared to taking placebo. There was found.
- Fig. 2 (B) shows that taking a proton pump inhibitor significantly It became clear that the frequency and duration of the pulses decreased.
- a double-blind test was performed on subjects (1) placebo, (2) probe pump inhibitor (rabebrazole sodium salt (lOmg; trade name: Noriet (registered trademark): Eisai Co., Ltd.), 3) histamine H 2 receptor antagonists (file Mochijin (lOmg; product name: Gaster (registered trademark): Yamanouchi Pharmaceutical Co., Ltd.) if the beauty (4) proton pump inhibitors (rabeprazole sodium salt (lOmg))
- Contact Yo Pi histamine H 2 receptor antagonists take (famotidine (LOmg)) both drugs ((4) at the same time taking the two agents) is, according to the method of test example 1, the muscle activity of the temporal muscle front portion of one side of the sleeping The amount was recorded for 1 hour after bedtime and for 4 hours up to 5 hours, and at the same time video images and audio were recorded, confirming that bruxism occurred during sleep.
- FIG. 3 shows the frequency of bruxism episodes per hour in each case after the co-administration of two receptor antagonists. The significance test was performed using the paired t test, and ⁇ ⁇ 0.05 was considered to be statistically significant.
- the combined administration group of a proton pump inhibitor and a histamine ⁇ 2 receptor antagonist reduced the frequency of bruxism episodes most.
- the following groups were treated with a proton pump inhibitor administration group, histamine ⁇ 2 receptor antagonist, and then in the order of bruxism episodes.
- Frequency of Moreover, the combination administration group and the proton pump inhibitor administration group of the proton pump inhibitor Contact Yopi histamine H 2 receptor antagonist, compared to placebo, significantly reduced the frequency of the probe Rakishizumuepiso one de.
- the gastric acid secretion inhibitor represented by the proton pump inhibitor according to the present invention has an effect of suppressing gastric acid reflux in the esophagus, which causes bruxism, and is associated with bruxism and bruxism. It is extremely useful in effective and fundamental prevention or treatment of disease.
- the present invention also leads to a significant reduction in the cost of treating bruxism and bruxism-related diseases, especially the cost of splint therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04706869.7A EP1611901B1 (en) | 2003-03-13 | 2004-01-30 | Preventive or remedy for teeth grinding |
US10/547,796 US7608625B2 (en) | 2003-03-13 | 2004-01-30 | Method for treating bruxism and bruxism-related diseases |
JP2005503460A JP4355703B2 (ja) | 2003-03-13 | 2004-01-30 | 歯ぎしりの予防剤または治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003068755 | 2003-03-13 | ||
JP2003-068755 | 2003-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004080487A1 true WO2004080487A1 (ja) | 2004-09-23 |
Family
ID=32984596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000939 WO2004080487A1 (ja) | 2003-03-13 | 2004-01-30 | 歯ぎしりの予防剤または治療剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7608625B2 (ja) |
EP (1) | EP1611901B1 (ja) |
JP (1) | JP4355703B2 (ja) |
WO (1) | WO2004080487A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009004475A (es) | 2006-10-27 | 2009-08-12 | Univ Missouri | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. |
CA2716367C (en) | 2008-02-20 | 2015-05-26 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028923A1 (en) * | 1993-06-10 | 1994-12-22 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
WO2001062290A2 (en) * | 2000-02-22 | 2001-08-30 | Cellegy Canada Inc. | Methods and compositions for improving sleep |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPH0643426B2 (ja) * | 1986-07-25 | 1994-06-08 | 東京田辺製薬株式会社 | イミダゾ〔4,5−b〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
FI90544C (fi) * | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
DK0585722T3 (da) * | 1992-08-21 | 1996-08-05 | Eisai Co Ltd | Benzimidazolderivater som antimikrobielt middel mod Campylobacter pylon |
ES2185693T3 (es) * | 1994-01-19 | 2003-05-01 | Sankyo Co | Derivado de pirrolopiridacina. |
SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
KR100550839B1 (ko) * | 1997-09-17 | 2006-02-10 | 에자이 가부시키가이샤 | 항균제 |
WO2005074536A2 (en) * | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
-
2004
- 2004-01-30 US US10/547,796 patent/US7608625B2/en not_active Expired - Fee Related
- 2004-01-30 WO PCT/JP2004/000939 patent/WO2004080487A1/ja active Application Filing
- 2004-01-30 EP EP04706869.7A patent/EP1611901B1/en not_active Expired - Lifetime
- 2004-01-30 JP JP2005503460A patent/JP4355703B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028923A1 (en) * | 1993-06-10 | 1994-12-22 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
WO2001062290A2 (en) * | 2000-02-22 | 2001-08-30 | Cellegy Canada Inc. | Methods and compositions for improving sleep |
Non-Patent Citations (5)
Title |
---|
"Principles and practice of sleep medicine", 2000, WB SAUNDERS, pages: 773 - 85 |
LOBBEZOO F; LAVIGNE GJ; TANGUAY R; MONTPLAISIR JY, MOV DISORD, vol. 12, 1997, pages 73 - 78 |
MARK H. BEERS AND ROBERT BERKOW: "The Merck Manual of dignosis and theraphy (17th ed.)", 1999, MERCK RESEARCH LABORATORIES, pages: 232 - 233, XP002977687 * |
MIYAWAKI, S. ET AL: "Association between nocturnal bruxism and gastroesophageal reflux", SLEEP, vol. 26, no. 7, 2003, pages 888 - 892, XP002977686 * |
See also references of EP1611901A4 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004080487A1 (ja) | 2006-06-08 |
US7608625B2 (en) | 2009-10-27 |
EP1611901B1 (en) | 2013-07-10 |
JP4355703B2 (ja) | 2009-11-04 |
US20060173045A1 (en) | 2006-08-03 |
EP1611901A4 (en) | 2010-01-20 |
EP1611901A1 (en) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2309371T3 (es) | Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de serotonina y/o norepinefrina y su uso para el tratamiento de trastornos funcionales de la vejiga urinaria. | |
JP3977724B2 (ja) | 医薬組成物 | |
EP0533281B1 (en) | The use of ranitidine bismuth citrate and in combination with claritromycin or claritromycin and tetracyclin in the manufacture of a medicament for treating gastrointestinal disorders | |
ES2890481T3 (es) | Usos del derivado de benzimidazol para la acidez gástrica nocturna | |
JP2012153712A (ja) | 胸やけの処置法 | |
JP2000511873A (ja) | 睡眠時呼吸障害を治療および診断する方法、並びにこの方法を実施する手段 | |
Kim et al. | Benign paroxysmal positional vertigo as a complication of sinus floor elevation | |
EP2964185B1 (en) | Preparations for the treatment of sleep-related respiratory disorders | |
EP1154795A1 (en) | Method of treating and diagnosing restless legs syndrome and corresponding means | |
JP3503953B2 (ja) | 睡眠無呼吸症候群の治療に有効な医薬の製造への特異的5ht▲下2▼レセプター拮抗薬の使用 | |
US20080161329A1 (en) | Pharmaceutical uses | |
US20100255096A1 (en) | Compositions And Methods For Transmucosal Delivery Of Domperidone | |
JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
JP2017078089A (ja) | 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ | |
RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
US20110152314A1 (en) | Use of tenatoprazole for the treatment of gastroesophageal reflux disease | |
JP2005097277A (ja) | 歯ぎしりの予防剤または治療剤 | |
WO2010087358A1 (ja) | 新規組成物 | |
WO2004080487A1 (ja) | 歯ぎしりの予防剤または治療剤 | |
JP2006523649A (ja) | 鬱病/不安の治療のためのパロキセチンおよび2−(r)−(4−フルオロ−2−メチル−フェニル)−4−(s)−((8as)−6−オキソ−ヘキサヒドロ−ピロロ[1,2−a]−ピラジン−2−イル)−ピペリジン−1−カルボン酸[1−(r)−(3,5−ビス−トリフルオロメチル−フェニル)−エチル]−メチルアミドの組み合わせ | |
WO2021014370A1 (en) | Pharmaceutical composition for use in the treatment and prevention of motion sickness | |
KR101153571B1 (ko) | 테나토프라졸 및 히스타민 h2-수용체 길항제를 배합한제약 조성물 | |
TWI676477B (zh) | 苯并咪唑衍生物用於夜間酸突破的用途 | |
JP5148801B2 (ja) | 催眠用固形製剤 | |
CN106822158B (zh) | 红景天苷用于防治阻塞性睡眠呼吸暂停诱导型高血压 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004706869 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006173045 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10547796 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005503460 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004706869 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10547796 Country of ref document: US |